Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations

M Carbone, HI Pass, G Ak, HR Alexander Jr… - Journal of Thoracic …, 2022 - Elsevier
The most common malignancies that develop in carriers of BAP1 germline mutations include
diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and …

Osteopontin as a link between inflammation and cancer: the thorax in the spotlight

AS Lamort, I Giopanou, I Psallidas, GT Stathopoulos - Cells, 2019 - mdpi.com
The glycoprotein osteopontin (OPN) possesses multiple functions in health and disease. To
this end, osteopontin has beneficial roles in wound healing, bone homeostasis, and …

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

A Scherpereel, I Opitz, T Berghmans… - European respiratory …, 2020 - Eur Respiratory Soc
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons
(ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for …

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

A Scherpereel, P Astoul, P Baas… - European …, 2010 - Eur Respiratory Soc
Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a
poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic …

Malignant pleural effusion: from bench to bedside

I Psallidas, I Kalomenidis, JM Porcel… - European …, 2016 - Eur Respiratory Soc
Malignant pleural effusion (MPE) is a common but serious condition that is related with poor
quality of life, morbidity and mortality. Its incidence and associated healthcare costs are …

Malignant mesothelioma

BWS Robinson, AW Musk, RA Lake - The Lancet, 2005 - thelancet.com
Malignant mesothelioma is an aggressive, treatment-resistant tumour, which is increasing in
frequency throughout the world. Although the main risk factor is asbestos exposure, a virus …

Malignant mesothelioma: facts, myths, and hypotheses

M Carbone, BH Ly, RF Dodson… - Journal of cellular …, 2012 - Wiley Online Library
Malignant mesothelioma (MM) is a neoplasm arising from mesothelial cells lining the
pleural, peritoneal, and pericardial cavities. Over 20 million people in the US are at risk of …

The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages

E Matsubara, H Yano, C Pan, Y Komohara, Y Fujiwara… - Cancers, 2023 - mdpi.com
Simple Summary Macrophages that infiltrate the cancer microenvironment are referred to as
tumor-associated macrophages (TAMs). Phosphoprotein 1 (SPP1), also known as …

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma

LM Krug, HI Pass, VW Rusch, HL Kindler… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural
pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy …

[HTML][HTML] Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma

HI Pass, SM Levin, MR Harbut… - … England Journal of …, 2012 - Mass Medical Soc
Background New biomarkers are needed to detect pleural mesothelioma at an earlier stage
and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and …